0000950170-22-016257 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2022	Aug. 02, 2022
Cover [Abstract]
Entity Registrant Name	TANGO THERAPEUTICS, INC.
Trading Symbol	TNGX
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001819133
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-39485
Entity Tax Identification Number	85-1195036
Entity Address, Address Line One	201 Brookline Ave.
Entity Address, Address Line Two	Suite 901
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02215
City Area Code	857
Local Phone Number	320-4900
Title of 12(b) Security	Common stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		88,041,404

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 104,582	$ 142,745
Marketable securities	311,774	342,510
Accounts receivable	2,000	2,000
Restricted cash	567	567
Prepaid expenses and other current assets	17,162	4,516
Total current assets	436,085	492,338
Property and equipment, net	8,359	4,832
Operating lease right-of-use assets	520	1,254
Restricted cash, net of current portion	3,423	1,712
Other assets	12	19
Total assets	448,399	500,155
Current liabilities:
Accounts payable	1,693	3,226
Accrued expenses and other current liabilities	14,161	9,887
Operating lease liabilities	629	1,503
Deferred revenue	28,200	26,022
Income tax payable	1	52
Total current liabilities	44,684	40,690
Deferred revenue, net of current portion	105,011	114,718
Total liabilities	149,695	155,408
Commitments and contingencies (Note 8)
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized at June 30, 2022 and December 31, 2021; 87,709,499 and 87,598,184 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	88	88
Additional paid-in capital	514,365	506,760
Accumulated other comprehensive loss	(4,347)	(765)
Accumulated deficit	(211,402)	(161,336)
Total stockholders' equity	298,704	344,747
Total liabilities and stockholders' equity	$ 448,399	$ 500,155

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Temporary Equity, Par or Stated Value Per Share	$ 0.001	$ 0.001
Temporary Equity, Shares Authorized	10,000,000	10,000,000
Temporary Equity, Shares Issued	0	0
Temporary Equity, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	87,997,949	87,598,184
Common Stock, Shares, Outstanding	87,997,949	87,598,184

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues	$ 5,771	$ 18,153	$ 11,529	$ 24,539
Operating expenses:
Research and development	23,741	19,079	48,071	34,079
General and administrative	7,232	3,630	14,039	7,097
Total operating expenses	30,973	22,709	62,110	41,176
Loss from operations	(25,202)	(4,556)	(50,581)	(16,637)
Other income (expense):
Interest income	297	104	515	208
Other income (expense), net	50	(62)	3	(117)
Total other income, net	347	42	518	91
Loss before income taxes	(24,855)	(4,514)	(50,063)	(16,546)
(Provision for) benefit from income taxes	(3)	21	(3)	(53)
Net loss	$ (24,858)	$ (4,493)	$ (50,066)	$ (16,599)
Net loss per common share - basic	$ (0.28)	$ (0.09)	$ (0.57)	$ (0.37)
Net loss per common share - diluted	$ (0.28)	$ (0.09)	$ (0.57)	$ (0.37)
Weighted average number of common shares outstanding - basic	87,839,804	48,524,511	87,775,440	45,088,434
Weighted average number of common shares outstanding - diluted	87,839,804	48,524,511	87,775,440	45,088,434
Net loss	$ (24,858)	$ (4,493)	$ (50,066)	$ (16,599)
Other comprehensive loss:
Unrealized loss on marketable securities	(937)	(30)	(3,582)	(15)
Comprehensive loss	(25,795)	(4,523)	(53,648)	(16,614)
Collaboration Revenue [Member]
Revenues	$ 5,771	7,153	$ 11,529	13,539
License Revenue [Member]
Revenues		$ 11,000		$ 11,000

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Redeemable Convertible Preferred Stock Series B [Member]
Balance at the beginning at Dec. 31, 2020	$ 38,600	$ 40	$ 141,644	$ 17	$ (103,101)
Balance at the beginning (in Shares) at Dec. 31, 2020		40,372,133
Issuance of redeemable convertible preferred stock, net of issuance costs						$ 29,990
Issuance of redeemable convertible preferred stock, net of issuance costs (in Shares)						22,686,025
Retroactive application of recapitalization	29,990	$ 8	29,982
Retroactive application of recapitalization (in Shares)		7,706,861
Retroactive application of recapitalization						$ (29,990)
Retroactive application of recapitalization (in Shares)						(22,686,025)
Exercise of stock options	440	$ 1	439
Exercise of stock options, (in Shares)		304,080
Vesting of restricted common stock awards	2		2
Stock based compensation expense	950		950
Other comprehensive income (loss)	15			15
Net loss	(12,106)				(12,106)
Balance at the ending at Mar. 31, 2021	57,891	$ 49	173,017	32	(115,207)
Balance at the ending (in Shares) at Mar. 31, 2021		48,383,074
Balance at the beginning at Dec. 31, 2020	38,600	$ 40	141,644	17	(103,101)
Balance at the beginning (in Shares) at Dec. 31, 2020		40,372,133
Net loss	(16,599)
Balance at the ending at Jun. 30, 2021	54,891	$ 49	174,540	2	(119,700)
Balance at the ending (in Shares) at Jun. 30, 2021		48,593,822
Balance at the beginning at Mar. 31, 2021	57,891	$ 49	173,017	32	(115,207)
Balance at the beginning (in Shares) at Mar. 31, 2021		48,383,074
Exercise of stock options	324		324
Exercise of stock options, (in Shares)		210,748
Vesting of restricted common stock awards	3		3
Stock based compensation expense	1,196		1,196
Other comprehensive income (loss)	(30)			(30)
Net loss	(4,493)				(4,493)
Balance at the ending at Jun. 30, 2021	54,891	$ 49	174,540	2	(119,700)
Balance at the ending (in Shares) at Jun. 30, 2021		48,593,822
Balance at the beginning at Dec. 31, 2021	344,747	$ 88	506,760	(765)	(161,336)
Balance at the beginning (in Shares) at Dec. 31, 2021		87,598,184
Exercise of stock options	265		265
Exercise of stock options, (in Shares)		111,315
Stock based compensation expense	3,205		3,205
Business combination and PIPE financing, issuance costs	(8)		(8)
Other comprehensive income (loss)	(2,645)			(2,645)
Net loss	(25,208)				(25,208)
Balance at the ending at Mar. 31, 2022	320,356	$ 88	510,222	(3,410)	(186,544)
Balance at the ending (in Shares) at Mar. 31, 2022		87,709,499
Balance at the beginning at Dec. 31, 2021	$ 344,747	$ 88	506,760	(765)	(161,336)
Balance at the beginning (in Shares) at Dec. 31, 2021		87,598,184
Exercise of stock options, (in Shares)	357,212
Net loss	$ (50,066)
Balance at the ending at Jun. 30, 2022	298,704	$ 88	514,365	(4,347)	(211,402)
Balance at the ending (in Shares) at Jun. 30, 2022		87,997,949
Balance at the beginning at Mar. 31, 2022	320,356	$ 88	510,222	(3,410)	(186,544)
Balance at the beginning (in Shares) at Mar. 31, 2022		87,709,499
Issuance of common stock from exercise of options and employee stock purchase plan	718		718
Issuance of common stock from exercise of options and employee stock purchase plan (in Shares)		288,450
Stock based compensation expense	3,425		3,425
Other comprehensive income (loss)	(937)			(937)
Net loss	(24,858)				(24,858)
Balance at the ending at Jun. 30, 2022	$ 298,704	$ 88	$ 514,365	$ (4,347)	$ (211,402)
Balance at the ending (in Shares) at Jun. 30, 2022		87,997,949

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Parenthetical) $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($)
Redeemable Convertible Preferred Stock Series B [Member]
Issuance of redeemable convertible preferred stock, net of issuance costs	$ 0.1

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (50,066)	$ (16,599)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	621	416
Noncash operating lease expense	735	492
Stock-based compensation	6,630	2,146
Other, net	15	118
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(12,646)	(395)
Other long-term assets	8	13
Accounts payable	(2,356)	2,749
Accrued expenses and other liabilities	4,260	(78)
Operating lease liabilities	(875)	(454)
Deferred revenue	(7,529)	(9,539)
Net cash used in operating activities	(61,203)	(21,131)
Cash flows from investing activities
Purchase of property and equipment	(3,372)	(367)
Sales and maturities of marketable securities	97,640	100,471
Purchases of marketable securities	(70,492)	(86,117)
Net cash provided by investing activities	23,776	13,987
Cash flows from financing activities
Proceeds from issuance of preferred stock, net of issuance costs		29,990
Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under ESPP	983	764
Payment of Business Combination and PIPE Financing transaction costs	(8)	(1,089)
Net cash provided by financing activities	975	29,665
Net change in cash, cash equivalents and restricted cash	(36,452)	22,521
Cash, cash equivalents and restricted cash, beginning of period	145,024	30,660
Cash, cash equivalents and restricted cash, end of period	108,572	53,181
Supplemental cash flow information:
Cash paid for leases	934	907
Supplemental disclosure of noncash investing and financing activity:
Purchases of property and equipment included in accounts payable and accrued expenses	$ 823	653
Merger with BCTG and PIPE financing deferred offering costs included in accounts payable and accrued expenses		$ 401

Nature of the Business and Basis of Presentation

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of the Business and Basis of Presentation

Tango Therapeutics, Inc. (“Tango” or the “Company”) is a precision oncology company committed to the discovery and development of novel drugs in defined patient populations with high unmet medical need.

Tango Therapeutics, Inc. (together with its consolidated subsidiaries, “Tango” or the “Company”) was incorporated in Delaware on May 21, 2020. On April 13, 2021, the Company, BCTG Merger Sub Inc., a Delaware corporation, and Tango Therapeutics, Inc. (now known as Tango Therapeutics Sub, Inc. or “Old Tango”) signed a definitive merger agreement (the "Merger Agreement"). Pursuant to the Merger Agreement, the business combination ("Business Combination") was approved on August 9, 2021 by shareholders of BCTG Acquisition Corp. ("BCTG"), resulting in BCTG acquiring 100% of Old Tango's issued and outstanding equity securities on August 10, 2021. As a result of the Business Combination, BCTG was renamed Tango Therapeutics, Inc.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements reflect the operations of Tango and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.

In the opinion of management, all adjustments necessary for a fair statement of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and six months ended June 30, 2022 and 2021 are not necessarily indicative of the results for the year ending December 31, 2022, any other interim periods, or any future year or period. The unaudited condensed consolidated financial statements for the three and six months ended June 30, 2022 and 2021 have been prepared on the same basis as and should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 28, 2022.

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no significant changes from the significant accounting policies disclosed in Note 2, Summary of Significant Accounting Policies, of the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Use of Estimates The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements.

Business Combination

6 Months Ended

Jun. 30, 2022

Business Combinations [Abstract]

Business Combination

3. Business Combination

On August 10, 2021 (the "Closing Date"), BCTG, a Delaware corporation and now predecessor of the Company, consummated the Business Combination, pursuant to the Merger Agreement, by and among BCTG, BCTG Merger Sub Inc., a Delaware corporation ("BCTG Merger Sub"), and Old Tango. Prior to consummation of the Business Combination, Old Tango changed its name from “Tango Therapeutics, Inc.” to “Tango Therapeutics Sub, Inc.” and in connection with the Business Combination, BCTG changed its name to “Tango Therapeutics, Inc.” (the former name of Old Tango). Pursuant to the Merger Agreement, on the Closing Date, BCTG Merger Sub merged with and into Old Tango, or the Merger, with Old Tango surviving the Merger as a wholly-owned subsidiary of BCTG, and (as noted above) BCTG changed its name to “Tango Therapeutics, Inc.”, or New Tango.

Pursuant to the terms and conditions of the Merger Agreement, the aggregate consideration paid to Old Tango equity holders upon the closing of the Merger was 55,000,000 shares of New Tango common stock. Subsequent to the closing of the Business Combination, New Tango entered into subscription agreements with certain investors ("PIPE Investors") pursuant to which the PIPE Investors purchased 18,610,000 shares of New Tango common stock at $10.00 per share, for aggregate gross proceeds of $186.1 million, under the PIPE Financing.

The following table summarizes the elements of the net proceeds from the Business Combination and PIPE Financing transaction (in thousands):


	Recapitalization
Cash - BCTG's Trust Account and cash (net of redemptions)	$	156,013
Cash - PIPE Financing		186,100
Less transaction costs and advisory fees paid		(15,844	)
Net cash proceeds from the Business Combination and PIPE Financing		326,269
Add: non-cash net assets assumed from BCTG		3
Net contributions from Business Combination and PIPE Financing	$	326,272

The following table summarizes the number of shares of common stock outstanding immediately following the consummation of the Business Combination and PIPE Financing transaction:


	Number of Shares
BCTG common shares outstanding prior to the Business Combination		21,377,250
Less redemption of BCTG shares		(1,106,814	)
Common shares of BCTG outstanding as of the Business Combination		20,270,436
Shares issued pursuant to the PIPE Financing		18,610,000
Business Combination and PIPE Financing shares		38,880,436
Old Tango common shares (after preferred shares were converted 1-for-1 for common shares)		48,593,803
Total shares of Common Stock immediately after Business Combination consummation		87,474,239

The merger consideration of 55,000,000 shares of New Tango common stock issued to Old Tango equity holders consists of 48,593,803 shares issued in exchange for Old Tango common and preferred shares outstanding, included in the table above, as well as 6,406,197 shares issued in exchange for the Old Tango unvested restricted stock awards and unexercised stock options outstanding immediately prior to the effective time of the Business Combination.

Retroactive Application of Recapitalization

As discussed above, the Business Combination with BCTG, which was consummated on August 10, 2021, is accounted for as a reverse recapitalization of equity structure. Under the reverse recapitalization model, the Business Combination was treated as Old Tango issuing equity for the net assets of BCTG, with no goodwill or intangible assets recorded. Under this method of accounting, BCTG was treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the Business Combination, Old Tango’s stockholders possess a majority of the voting power of the combined company, the combined company comprises all of the ongoing operations of Old Tango, the combined company comprises a majority of the

governing body of Old Tango, and the combined company’s senior management comprises all of the senior management of Old Tango.

These unaudited condensed consolidated financial statements contain recasted stockholders' equity balances resulting from the retroactive application of reverse recapitalization accounting in accordance with U.S. GAAP.

Pursuant to the terms of the Merger Agreement, upon the closing of the Business Combination on August 10, 2021 (the “Effective Time”), each share of Old Tango’s redeemable convertible preferred stock (the “Preferred Stock”) issued and outstanding immediately prior to the Effective Time was converted into a share of the Company’s common stock using the exchange ratio of 0.34.

All common shares, as well as previously issued share options and restricted stock awards (“RSAs”), presented in the accompanying unaudited recasted condensed consolidated statements of redeemable convertible preferred stock and stockholders' equity and/or in the related notes are presented on an as-converted basis, converted at the ratio of 0.34. The basic and diluted weighted-average shares of common stock outstanding for the three and six months ended June 30, 2021 has been retroactively converted using the exchange ratio of 0.34. The historical proceeds from the issuance of preferred stock, less the par value of the historical preferred shares that were converted into common shares using the 0.34 ratio at the Effective Time, have been reclassified to additional paid in capital for the three and six months ended June 30, 2021.

Date

Description

Redeemable Convertible Preferred Stock

Preferred to Common Exchange Ratio

Common Stock Shares

8/10/2021 Merger Recapitalization Exchange Ratio

Recapitalization Common Stock

3/18/2021

Series B (tranche 2)

22,686,025

1.00

22,686,025

0.34

7,706,861

The following table summarizes the weighted-average common shares, basic and diluted, for the three months ended June 30, 2021:


Date	Description	As previously recorded		8/10/2021 Merger Exchange Ratio		Recapitalized Common Stock		Days Outstanding in Q2 2021	% of weighting	Weighted average common shares
6/30/2021	Weighted-average shares, basic and diluted		14,485,746		0.34		4,965,270	91	100%		4,965,270
12/31/2019	Series A shares		55,700,000		0.34		18,922,317	91	100%		18,922,317
4/7/2020	Series B shares		22,686,025		0.34		7,706,443	91	100%		7,706,443
8/17/2020	Series B-1 shares		27,152,255		0.34		9,223,621	91	100%		9,223,621
3/18/2021	Series B shares (tranche 2)		22,686,025		0.34		7,706,861	91	100%		7,706,861
Weighted average number of common shares outstanding – basic and diluted for the three months ended June 30, 2021											48,524,511

The following table summarizes the weighted-average common shares, basic and diluted, for the six months ended June 30, 2021:


Date	Description	As previously recorded		8/10/2021 Merger Exchange Ratio		Recapitalized Common Stock		Days Outstanding in 2021	% of weighting	Weighted average common shares
6/30/2021	Weighted-average shares, basic and diluted		14,214,543		0.34		4,807,132	181	100%		4,807,132
12/31/2019	Series A shares		55,700,000		0.34		18,922,317	181	100%		18,922,317
4/7/2020	Series B shares		22,686,025		0.34		7,706,443	181	100%		7,706,443
8/17/2020	Series B-1 shares		27,152,255		0.34		9,223,621	181	100%		9,223,621
3/18/2021	Series B shares (tranche 2)		22,686,025		0.34		7,706,861	105	57%		4,428,922
Weighted average number of common shares outstanding – basic and diluted for the six months ended June 30, 2021											45,088,434

Collaboration Agreements

6 Months Ended

Jun. 30, 2022

Collaboration Agreements [Abstract]

Collaboration Agreements

2018 Gilead Agreement

In October 2018, the Company entered into a Research Collaboration and License Agreement (the “2018 Gilead Agreement”) with Gilead Sciences, Inc. (“Gilead”). Pursuant to the 2018 Gilead Agreement, the Company performed target discovery and validation activities in accordance with an agreed-upon multi-year research plan. During the initial three-year research term, Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to five validated programs (“Gilead Program License”).

In 2018, Gilead paid the Company a $50.0 million non-refundable upfront payment upon the execution of the 2018 Gilead Agreement. The Company was eligible to receive milestone payments of up to $1.7 billion across all programs and royalties on future sales of commercialized products, if any. For up to two programs licensed by Gilead, the Company had the option to co-develop and co-promote certain programs licensed by Gilead in the U.S. and was eligible to receive royalties on ex-U.S. sales.

The Company assessed this arrangement in accordance with ASC 606, Revenue from Contracts with Customers, and concluded that the contract counterparty, Gilead, was a customer. The Company identified a single performance obligation under the arrangement consisting of the combination of participating on the joint steering committee and the research and development services provided during the research term. The identified promises were determined to not be individually distinct due to the specialized nature of the early-stage research services to be provided by the Company and the interdependent relationship between the promises. The Company determined that the option for Gilead to extend the term of the arrangement was not priced at a discount, and therefore did not provide Gilead with a material right. This option will be excluded from the transaction price until exercised. At the inception of the 2018 Gilead Agreement, the Company also determined that the Gilead program license options provided to Gilead did not include a material right.

The total transaction price, subject to variable consideration constraints, was allocated to the combined single performance obligation. The Company determined that the single combined performance obligation is satisfied over time as the customer is simultaneously receiving and consuming the benefit of the Company’s performance. The future milestone payments represent variable consideration that is fully constrained at inception of the arrangement as the achievement of the milestone events are highly uncertain.

Amended Gilead Agreement

In August 2020, Gilead made an equity investment of $20.0 million into the Company as a participant in the Company’s Series B-1 preferred stock offering. At the time of the original investment, as well as of the June 30, 2022 balance sheet date, Gilead maintains an ownership of less than 10% of the Company's common stock and is thus not considered to be a related party to the Company.

In August 2020, the Company and Gilead also entered into an Amended Research Collaboration and License Agreement (the “Gilead Agreement”), which superseded and replaced the 2018 Gilead Agreement. The Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the 2018 Gilead Agreement. Under the Gilead Agreement:

•

The Company received upfront, non-refundable consideration of $125.0 million from Gilead upon execution of the Gilead Agreement in 2020;

•

The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement has a research term of seven years;

•

Gilead expanded its option to license up to 15 programs for which Gilead may obtain exclusive, worldwide licenses to develop and commercialize therapies, subject to applicable license fees;

•

Prior to exercising its option to license a program, Gilead may “extend” such program, in which case Gilead will pay research extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development;

•

Gilead has the option to “reserve” a target during which Gilead may: (i) license the target, (ii) “extend” the target, or (iii) decline the target, during the designated reserve target period. If, during the reserve target period Tango elects to work on the reserved target, Tango will retain full rights to the target program and Gilead receives a right of first negotiation in connection with any future partnering or licensing of such target by Tango, if any; and

•

For up to five programs licensed by Gilead, the Company has the option to co-develop and co-promote the lead product in the U.S., subject to certain exceptions, and is eligible to receive tiered royalties in the first decile on ex-U.S. sales.

The Company is eligible to receive up to $410.0 million per program in license, research extension, and clinical, regulatory, and commercial milestones and royalties on future sales of commercialized products, if any.

The Gilead Agreement was accounted for as a modification of the 2018 Gilead Agreement under ASC 606 as both the scope and price of the contract were changed under the Gilead Agreement. The additional goods and services to be provided under the Gilead Agreement are not distinct from the combined performance obligation identified under the 2018 Gilead Agreement which was only partially satisfied at the date of contract modification. As such, the Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering committee during the

research term. As a result, the Company’s progress towards completing its research services to Gilead over the seven-year term of the Gilead Agreement was lower than its progress under the three-year term of the 2018 Gilead Agreement and a cumulative catch-up adjustment was recorded during the third quarter of 2020 resulting in a charge of $11.3 million against revenue previously recognized through the date of the Gilead Agreement.

In December 2020 and in September 2021, Gilead elected to extend two programs for a research extension fee of $12.0 million each. The Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the on-going research plan. Consideration pertaining to each of the research extensions is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. Although future research installment payments are not payable in the event of scientific failure, the Company determined that the variable consideration of $12.0 million for each of the extensions should not be constrained as the potential for a significant reversal of cumulative revenue recognized at the contract level is remote, and therefore the research extension consideration was added to the transaction price under the Gilead Agreement.

In April 2021, Gilead licensed a program for an $11.0 million license fee. The $11.0 million license fee was received and recognized as revenue in the second quarter of 2021 since Tango has no continued involvement in the advancement of the program, Gilead can benefit from the license on its own and the license is separately identifiable from the research services.

Gilead Revenue Recognized

The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $199.0 million at June 30, 2022. The total transaction price was comprised of the $50.0 million upfront payment pursuant to the 2018 Gilead Agreement, the $125.0 million upfront payment pursuant to the Gilead Agreement, the $12.0 million payment pursuant to the research extension fee in December 2020, and the $12.0 million payment pursuant to the research extension fee in September 2021. During the six months ended June 30, 2022 and 2021, the Company recognized $11.5 million and $13.5 million, respectively, of collaboration revenue associated with the Gilead agreements based on performance completed during each period.

The Company reevaluates the transaction price and the total estimated costs expected to be incurred to satisfy the performance obligations at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the Company is responsible for, are resolved or other changes in circumstances occur. As of June 30, 2022 and December 31, 2021, the Company had short-term deferred revenue of $28.2 million and $26.0 million, respectively, and long-term deferred revenue of $105.0 million and $114.7 million, respectively, related to the Gilead collaboration. The remaining long-term revenue is expected to be recognized proportionally to the completed obligations over an expected remaining contractual term of approximately 5.1 years.

Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company’s unaudited condensed consolidated balance sheets. As of June 30, 2022, $6.0 million of the ongoing research extension fee total of $12.0 million had been received, $2.0 million had been recorded as accounts receivable and the remaining $4.0 million was determined to be conditional upon the satisfaction of additional research obligations, and thus a contract asset. The contract asset balance is presented net of the deferred revenue contract liability.

Costs incurred pursuant to the Gilead Agreements are recorded as research and development expense.

Fair Value Measurements

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis:


	Fair Market Value Measurements as of June 30, 2022
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents:
Money market funds	$	39,303	$	—	$	—	$	39,303
U.S. Treasury bills		—		12,893		—		12,893
Marketable debt securities:
U.S. Treasury bills		—		236,359		—		236,359
U.S. government agency bonds		—		75,415		—		75,415
Total assets	$	39,303	$	324,667	$	—	$	363,970


	Fair Market Value Measurements as of December 31, 2021
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents
Money market funds	$	62,244	$	—	$	—	$	62,244
U.S. Treasury bills		—		38,433		—		38,433
Marketable debt securities
U.S. Treasury bills		—		287,123		—		287,123
U.S. government agency bonds		—		55,387		—		55,387
Total assets	$	62,244	$	380,943	$	—	$	443,187

There were no transfers between fair value levels during the six months ended June 30, 2022.

Supplemental Balance Sheet Information

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental Balance Sheet Information

Property and Equipment

Property and equipment, net as of June 30, 2022 and December 31, 2021 consists of the following:


	June 30, 2022			December 31, 2021
	(in thousands)
Laboratory equipment	$	5,860		$	5,587
Computer equipment		198			198
Computer software		125			125
Furniture and fixtures		467			467
Leasehold improvements		246			246
Construction in progress		4,606			738
		11,502			7,361
Less: Accumulated depreciation		(3,143	)		(2,529	)
Property and equipment, net	$	8,359		$	4,832

Depreciation expense was $0.6 million and $0.4 million for the six months ended June 30, 2022 and 2021, respectively.

At June 30, 2022, the balance of construction in process includes construction costs for lessee-owned improvements and costs associated with laboratory equipment under installation at the leased office and laboratory premises at 201 Brookline Avenue. The in-progress construction projects are expected to be completed and the 201 Brookline Avenue lease is expected to commence in the third quarter of 2022.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities as of June 30, 2022 and December 31, 2021 include the following:


	June 30, 2022		December 31, 2021
	(in thousands)
Payroll and employee-related costs	$	2,926	$	3,688
Research and development costs		10,318		5,533
Other		917		666
Total accrued expenses and other current liabilities	$	14,161	$	9,887

Restricted Cash

As of June 30, 2022 and 2021, the Company maintained a restricted cash balance of $4.0 million and $2.3 million, respectively, all of which was related to security deposits associated with the Company’s facility leases. The cash will remain restricted in accordance with the lease agreements absent the event of a lease termination or modification. The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the condensed consolidated statements of cash flows are as follows:


	June 30, 2022		June 30, 2021
	(in thousands)
Cash and cash equivalents	$	104,582	$	50,902
Restricted cash		3,990		2,279
Cash, cash equivalents and restricted cash	$	108,572	$	53,181

Commitments and Contingencies

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Other Funding Commitments

As of June 30, 2022, the Company had ongoing preclinical and clinical studies. The Company enters into contracts in the normal course of business with contract research organizations in connection with the operation and preparation for clinical trials,

professional consultants for expert advice and other vendors for clinical supply manufacturing or other preclinical services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.

Guarantees

The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, construction companies, contract research organizations, clinical trial sites, and other parties. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party under the terms of the contract, including as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.

Litigation

The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of June 30, 2022, and no material legal proceedings are currently pending or threatened. Because of uncertainties related to claims, proceedings and litigation, assessments of potential liabilities are based on the Company's best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse effect on the operating results of the Company. Costs associated with involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were to be unable to prevail in any such proceedings, the consolidated financial position, results of operations, and future cash flows of the Company may be materially impacted.

Redeemable Convertible Preferred Stock

6 Months Ended

Jun. 30, 2022

Temporary Equity Disclosure [Abstract]

Redeemable Convertible Preferred Stock

In March 2021, Old Tango sold 22,686,025 additional shares of Series B stock at a price of $1.32 per share upon the achievement of specified development milestones in connection with the second tranche of the Series B stock purchase agreement. Proceeds from this issuance totaled $30.0 million. Total issuance costs associated with the March 2021 issuance of Series B preferred stock was less than $0.1 million.

Conversion of Redeemable Convertible Preferred Stock

Pursuant to the terms of the Merger Agreement, upon the Effective Time, each share of Old Tango’s Preferred Stock issued and outstanding immediately prior to the Effective Time was converted into a share of Old Tango’s common stock and subsequently converted into shares of New Tango common stock using an exchange ratio of 0.34. A retroactive adjustment has been applied to all periods presented to reflect the Business Combination and reverse recapitalization, therefore, resulting in no outstanding Preferred Stock as of June 30, 2022 and 2021. Refer to Note 3 for additional discussion.

Undesignated Preferred Stock

The Company’s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of preferred stock with a par value of $0.001 per share. The number of shares of preferred stock authorized to be issued is 10,000,000 shares as of June 30, 2022. The shares of preferred stock are currently undesignated.

Stock-Based Compensation

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

10.

Stock-Based Compensation

Stock Incentive Plan

In March 2017, Old Tango's stockholders approved the 2017 Stock Option and Grant Plan, pursuant to which Old Tango issued stock options, restricted stock awards (“RSAs”), unrestricted stock awards, restricted stock units, or any combination of the forgoing to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company.

The 2021 Stock Option and Incentive Plan (the “2021 Plan”) became effective upon the closing of the Business Combination and replaced the 2017 Stock Option and Grant Plan. The 2021 Plan allows the Company to make equity and equity-based incentive

awards to officers, employees, non-employee directors and consultants. As of June 30, 2022, the Company had 7,049,248 shares available for future issuance under the 2021 Plan.

The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
	(in thousands)				(in thousands)
Research and development	$	1,656	$	552	$	3,298	$	1,012
General and administrative		1,769		644		3,332		1,134
Total	$	3,425	$	1,196	$	6,630	$	2,146

Stock Option Activity

Pursuant to the terms of the Business Combination, upon the Closing Date, each option to purchase Old Tango’s common stock became an option to purchase shares of common stock of the surviving entity and was subsequently adjusted using an exchange ratio of 0.34. A retroactive adjustment has been applied to all periods presented to reflect the Business Combination and reverse recapitalization as discussed further in Note 3.

The following table summarizes the stock option activity for the six months ended June 30, 2022:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Contractual Term		Aggregate Intrinsic Value
	(in years)
Options outstanding as of December 31, 2021		9,372,993		$	5.59		8.55	$	51,415,394
Granted		4,132,175			8.88
Exercised		(357,212	)		2.01
Cancelled		(713,745	)		9.47
Options outstanding as of June 30, 2022		12,434,211		$	6.56		8.59	$	9,642,834
Options exercisable as of June 30, 2022		3,096,025		$	3.16		7.01	$	6,047,673

As of June 30, 2022, total unrecognized compensation expense related to stock options was $42.5 million, which the Company expects to recognize over a remaining weighted-average period of 2.9 years.

2021 Employee Stock Purchase Plan

The 2021 Employee Stock Purchase Plan (the “2021 ESPP”) was adopted and approved by the Company’s board of directors and by the Company’s stockholders and became effective upon the closing of the Business Combination. During the six months ended June 30, 2022, the Company issued 42,553 shares of common stock under the 2021 ESPP.

Net Loss Per Share

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

11.

Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	(in thousands, except per share data)						(in thousands, except per share data)
	2022			2021			2022			2021
Numerator:
Net loss	$	(24,858	)	$	(4,493	)	$	(50,066	)	$	(16,599	)
Denominator:
Weighted-average common stock outstanding – basic and diluted		87,839,804			48,524,511			87,775,440			45,088,434
Net loss per common share – basic and diluted	$	(0.28	)	$	(0.09	)	$	(0.57	)	$	(0.37	)

The Company’s potential dilutive securities, which include common stock options and unvested restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the

weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	June 30,
	2022		2021
Stock options to purchase common stock		12,434,211		6,494,737
Unvested restricted common stock		—		5,524
Total		12,434,211		6,500,261

Income Taxes

6 Months Ended

Jun. 30, 2022

Income Tax Disclosure [Abstract]

Income Taxes

12.

Income Taxes

The Company’s effective income tax rate was 0.0% and -0.3% for the three months ended June 30, 2022 and 2021, respectively, and 0.0% and -0.3% for the six months ended June 30, 2022 and 2021, respectively. The income tax provision was $3 thousand and the income tax benefit was $21 thousand for the three months ended June 30, 2022 and 2021, respectively, and the income tax provision was $3 thousand and $53 thousand for the six months ended June 30, 2022 and 2021, respectively. The change in the provision for income taxes for the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 was primarily due to taxable deferred revenue in 2021 partially offset by the utilization of federal and state net operating losses and federal and state tax credits. For 2022, the Company assessed the new requirement to capitalize and amortize research and experimentation expenditures for U.S. tax purposes, which became effective as of January 1, 2022. The Company is forecasting a taxable loss position in 2022 for which no tax benefit is recorded due to the valuation allowance maintained against the Company’s deferred tax assets.

The effective income tax rate for the three and six months ended June 30, 2022 and 2021 differed from the federal statutory rate primarily due to the valuation allowance maintained against the Company’s deferred tax assets.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements.

Business Combination (Tables)

6 Months Ended

Jun. 30, 2022

Business Combinations [Abstract]

Summary of Net Proceeds from Business Combination and PIPE Financing Transactions

The following table summarizes the elements of the net proceeds from the Business Combination and PIPE Financing transaction (in thousands):


	Recapitalization
Cash - BCTG's Trust Account and cash (net of redemptions)	$	156,013
Cash - PIPE Financing		186,100
Less transaction costs and advisory fees paid		(15,844	)
Net cash proceeds from the Business Combination and PIPE Financing		326,269
Add: non-cash net assets assumed from BCTG		3
Net contributions from Business Combination and PIPE Financing	$	326,272

Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction

The following table summarizes the number of shares of common stock outstanding immediately following the consummation of the Business Combination and PIPE Financing transaction:


	Number of Shares
BCTG common shares outstanding prior to the Business Combination		21,377,250
Less redemption of BCTG shares		(1,106,814	)
Common shares of BCTG outstanding as of the Business Combination		20,270,436
Shares issued pursuant to the PIPE Financing		18,610,000
Business Combination and PIPE Financing shares		38,880,436
Old Tango common shares (after preferred shares were converted 1-for-1 for common shares)		48,593,803
Total shares of Common Stock immediately after Business Combination consummation		87,474,239

Summary of Weighted-Average Common Shares, Basic and Diluted

Date

Description

Redeemable Convertible Preferred Stock

Preferred to Common Exchange Ratio

Common Stock Shares

8/10/2021 Merger Recapitalization Exchange Ratio

Recapitalization Common Stock

3/18/2021

Series B (tranche 2)

22,686,025

1.00

22,686,025

0.34

7,706,861

The following table summarizes the weighted-average common shares, basic and diluted, for the three months ended June 30, 2021:


Date	Description	As previously recorded		8/10/2021 Merger Exchange Ratio		Recapitalized Common Stock		Days Outstanding in Q2 2021	% of weighting	Weighted average common shares
6/30/2021	Weighted-average shares, basic and diluted		14,485,746		0.34		4,965,270	91	100%		4,965,270
12/31/2019	Series A shares		55,700,000		0.34		18,922,317	91	100%		18,922,317
4/7/2020	Series B shares		22,686,025		0.34		7,706,443	91	100%		7,706,443
8/17/2020	Series B-1 shares		27,152,255		0.34		9,223,621	91	100%		9,223,621
3/18/2021	Series B shares (tranche 2)		22,686,025		0.34		7,706,861	91	100%		7,706,861
Weighted average number of common shares outstanding – basic and diluted for the three months ended June 30, 2021											48,524,511

The following table summarizes the weighted-average common shares, basic and diluted, for the six months ended June 30, 2021:


Date	Description	As previously recorded		8/10/2021 Merger Exchange Ratio		Recapitalized Common Stock		Days Outstanding in 2021	% of weighting	Weighted average common shares
6/30/2021	Weighted-average shares, basic and diluted		14,214,543		0.34		4,807,132	181	100%		4,807,132
12/31/2019	Series A shares		55,700,000		0.34		18,922,317	181	100%		18,922,317
4/7/2020	Series B shares		22,686,025		0.34		7,706,443	181	100%		7,706,443
8/17/2020	Series B-1 shares		27,152,255		0.34		9,223,621	181	100%		9,223,621
3/18/2021	Series B shares (tranche 2)		22,686,025		0.34		7,706,861	105	57%		4,428,922
Weighted average number of common shares outstanding – basic and diluted for the six months ended June 30, 2021											45,088,434

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Summary of Financial Assets Measured at Fair Value on a Recurring Basis

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis:


	Fair Market Value Measurements as of June 30, 2022
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents:
Money market funds	$	39,303	$	—	$	—	$	39,303
U.S. Treasury bills		—		12,893		—		12,893
Marketable debt securities:
U.S. Treasury bills		—		236,359		—		236,359
U.S. government agency bonds		—		75,415		—		75,415
Total assets	$	39,303	$	324,667	$	—	$	363,970


	Fair Market Value Measurements as of December 31, 2021
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents
Money market funds	$	62,244	$	—	$	—	$	62,244
U.S. Treasury bills		—		38,433		—		38,433
Marketable debt securities
U.S. Treasury bills		—		287,123		—		287,123
U.S. government agency bonds		—		55,387		—		55,387
Total assets	$	62,244	$	380,943	$	—	$	443,187

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Supplemental Balance Sheet Information (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Property, Plant and Equipment

Property and equipment, net as of June 30, 2022 and December 31, 2021 consists of the following:


	June 30, 2022			December 31, 2021
	(in thousands)
Laboratory equipment	$	5,860		$	5,587
Computer equipment		198			198
Computer software		125			125
Furniture and fixtures		467			467
Leasehold improvements		246			246
Construction in progress		4,606			738
		11,502			7,361
Less: Accumulated depreciation		(3,143	)		(2,529	)
Property and equipment, net	$	8,359		$	4,832

Schedule of Accrued Expenses and Other Current Liabilities Current

Accrued expenses and other current liabilities as of June 30, 2022 and December 31, 2021 include the following:


	June 30, 2022		December 31, 2021
	(in thousands)
Payroll and employee-related costs	$	2,926	$	3,688
Research and development costs		10,318		5,533
Other		917		666
Total accrued expenses and other current liabilities	$	14,161	$	9,887

Schedule of Cash, Cash Equivalents Restricted Cash and Restricted Cash Equivalents

The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the condensed consolidated statements of cash flows are as follows:


	June 30, 2022		June 30, 2021
	(in thousands)
Cash and cash equivalents	$	104,582	$	50,902
Restricted cash		3,990		2,279
Cash, cash equivalents and restricted cash	$	108,572	$	53,181

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Summary of Stock-based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
	(in thousands)				(in thousands)
Research and development	$	1,656	$	552	$	3,298	$	1,012
General and administrative		1,769		644		3,332		1,134
Total	$	3,425	$	1,196	$	6,630	$	2,146

Summary of Stock Option Activity

The following table summarizes the stock option activity for the six months ended June 30, 2022:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Contractual Term		Aggregate Intrinsic Value
	(in years)
Options outstanding as of December 31, 2021		9,372,993		$	5.59		8.55	$	51,415,394
Granted		4,132,175			8.88
Exercised		(357,212	)		2.01
Cancelled		(713,745	)		9.47
Options outstanding as of June 30, 2022		12,434,211		$	6.56		8.59	$	9,642,834
Options exercisable as of June 30, 2022		3,096,025		$	3.16		7.01	$	6,047,673

As of June 30, 2022, total unrecognized compensation expense related to stock options was $42.5 million, which the Company

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	(in thousands, except per share data)						(in thousands, except per share data)
	2022			2021			2022			2021
Numerator:
Net loss	$	(24,858	)	$	(4,493	)	$	(50,066	)	$	(16,599	)
Denominator:
Weighted-average common stock outstanding – basic and diluted		87,839,804			48,524,511			87,775,440			45,088,434
Net loss per common share – basic and diluted	$	(0.28	)	$	(0.09	)	$	(0.57	)	$	(0.37	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	June 30,
	2022		2021
Stock options to purchase common stock		12,434,211		6,494,737
Unvested restricted common stock		—		5,524
Total		12,434,211		6,500,261

Nature of the Business and Basis of Presentation - Additional Information (Details)	Aug. 10, 2021
Merger Agreement [Member]
Business acquisition, percentage of voting interest	100.00%

Business Combination - Additional Information (Details)	Aug. 11, 2021 USD ($) $ / shares shares	Aug. 10, 2021 USD ($) shares	Jun. 30, 2022	Jun. 30, 2021
Business Acquisition [Line Items]
Merger exchange ratio		0.34	0.34	0.34
Shares issued in exchange for Unvested restricted stock awards and unexercised stock options		6,406,197
Private Placement [Member]
Business Acquisition [Line Items]
Number of units issued in transaction (in Shares)	18,610,000
Gross proceeds \| $	$ 186,100,000
Price per share (in Dollars per share) \| $ / shares	$ 10.00
Merger Agreement [Member]
Business Acquisition [Line Items]
Acquisition date		Aug. 10, 2021
Number of units issued in transaction (in Shares)		55,000,000
BCTG Acquisition Corp [Member]
Business Acquisition [Line Items]
Goodwill \| $		$ 0
Intangible assets \| $		$ 0
Tango Therapeutics, Inc [Member]
Business Acquisition [Line Items]
Outstanding common shares		48,593,803

Business Combination - Summary of Net Proceeds from Business Combination and PIPE Financing Transactions (Details) $ in Thousands	Aug. 10, 2021 USD ($)
PIPE Financing [Member]
Business Acquisition [Line Items]
Cash	$ 186,100
BCTG's Trust Account [Member]
Business Acquisition [Line Items]
Cash	156,013
BCTG Business Combination and PIPE Financing [Member]
Business Acquisition [Line Items]
Less transaction costs and advisory fees paid	(15,844)
Net cash proceeds from the Business Combination and PIPE Financing	326,269
Net contributions from Business Combination and PIPE Financing	326,272
BCTG Acquisition Corp [Member]
Business Acquisition [Line Items]
Add: non-cash net assets assumed from BCTG	$ 3

Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction (Details) - shares	Jun. 30, 2022	Dec. 31, 2021	Aug. 10, 2021
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Common shares outstanding	87,997,949	87,598,184	87,474,239
BCTG Acquisition Corp [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Common shares outstanding prior to business combination			21,377,250
Less redemption of BCTG shares			1,106,814
Common shares outstanding			20,270,436
BCTG Business Combination and PIPE Financing [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Shares issued pursuant to the PIPE Financing			38,880,436
Tango Therapeutics, Inc [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Old Tango common shares (after preferred shares were converted 1-for-1 for common shares)			48,593,803
PIPE Financing [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Shares issued pursuant to the PIPE Financing			18,610,000

Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transactions (Parenthetical) (Details)	Aug. 10, 2021
Tango Therapeutics, Inc [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Share conversion ratio	1

Business Combination - Summary of Weighted-Average Common Shares, Basic and Diluted (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Jun. 30, 2022 shares	Jun. 30, 2021 shares	Dec. 31, 2021 shares	Aug. 10, 2021	Mar. 18, 2021 shares
Class of Stock [Line Items]
Weighted average common shares, basic	87,839,804	48,524,511	87,775,440	45,088,434
Weighted average common shares, diluted	87,839,804	48,524,511	87,775,440	45,088,434
Merger Exchange Ratio	0.34	0.34	0.34	0.34		0.34
Common Stock Shares	87,997,949		87,997,949		87,598,184
Temporary Equity, Shares Issued	0		0		0
Preferred to Common exchange ratio	0.34		0.34
Series B shares (tranche 2)
Class of Stock [Line Items]
Merger Exchange Ratio						0.34
Recapitalization Common Stock							7,706,861
Common Stock Shares							22,686,025
Temporary Equity, Shares Issued							22,686,025
Preferred to Common exchange ratio							1.00

Collaboration Agreements - Additional Information (Details)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2021 USD ($)	Aug. 31, 2020 USD ($) Program	Oct. 31, 2018 Program	Jun. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from fees received						$ 6,000,000.0
Accounts receivable current, research extension fee						2,000,000.0
Contract asset, research extension fee						4,000,000.0
Receivable research extension fee						12,000,000.0
2018 Gilead Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research term			3 years
Number of licensed product \| Program			5
Non-refundable upfront payment received						50,000,000.0		$ 50,000,000.0
Milestone payments receivable								$ 1,700,000,000
Amended Gilead Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research term		7 years
Number of licensed product \| Program		15
Non-refundable upfront payment received						125,000,000.0
Milestone payments receivable		$ 410,000,000.0
Temporary equity, par value		125,000,000.0
Revenue recognized, cumulative catch-up adjustment					$ (11,300,000)
Research extension fee										$ 12,000,000.0	$ 12,000,000.0
Research extension fees, variable consideration						$ 12,000,000.0
Contract with customer liability, revenue recognized				$ 11,000,000.0
License fee amount	$ 11,000,000.0
Amended Gilead Agreement [Member] \| Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Equity method investment, ownership percentage						10.00%
Amended Gilead Agreement [Member] \| Series B-1 Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Temporary equity, par value		$ 20,000,000.0
Gilead Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Transaction price allocated to performance obligation						$ 199,000,000.0
Short-term deferred revenue						28,200,000			$ 26,000,000.0
Long-term deferred revenue						105,000,000.0			$ 114,700,000
Collaboration Revenue [Member] \| Gilead Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer liability, revenue recognized						$ 11,500,000	$ 13,500,000

Collaboration Agreements - Additional Information (Details1)	Jun. 30, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-21
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue remaining performance obligations expected remaining contractual term	5 years 1 month 6 days

Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value Measurements Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, Money market funds	$ 39,303	$ 62,244
Cash equivalents, U.S. Treasury bills	12,893	38,433
Total assets	363,970	443,187
Marketable Debt Securities [Member] \| U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	236,359	287,123
Marketable Debt Securities [Member] \| U.S. Government Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	75,415	55,387
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, Money market funds	39,303	62,244
Total assets	39,303	62,244
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, U.S. Treasury bills	12,893	38,433
Total assets	324,667	380,943
Level 2 [Member] \| Marketable Debt Securities [Member] \| U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	236,359	287,123
Level 2 [Member] \| Marketable Debt Securities [Member] \| U.S. Government Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable debt securities	$ 75,415	$ 55,387

Marketable Securities - Summary of Debt Securities, Available For Sale (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 316,121	$ 343,275
Gross Unrealized Gains	6	1
Gross Unrealized Loss	(4,353)	(766)
Fair Value	311,774	342,510
U.S. Treasury Bills [Member] \| Marketable Debt Securities [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	239,660	287,699
Gross Unrealized Gains		1
Gross Unrealized Loss	(3,301)	(577)
Fair Value	236,359	287,123
U.S. Government Agency Bonds [Member] \| Marketable Debt Securities [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	76,461	55,576
Gross Unrealized Gains	6
Gross Unrealized Loss	(1,052)	(189)
Fair Value	$ 75,415	$ 55,387

Marketable Securities - Additional Information (Details) - Marketable Debt Securities [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Debt Securities, Available-for-Sale [Line Items]
Impairments to marketable securities or reserves for credit losses	$ 0	$ 0
Marketable securities, Accrued interest	300,000	200,000
U.S. Government Agency Bonds [Member]
Debt Securities, Available-for-Sale [Line Items]
Debt securities considered to be an unrealized loss position		$ 800,000
U.S.Treasury Bills And U.S.Government Agency Bonds
Debt Securities, Available-for-Sale [Line Items]
Debt securities considered to be an unrealized loss position	$ 4,400,000

Supplemental Balance Sheet Information - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Depreciation expense	$ 621	$ 416
Security Deposits [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Restricted cash	$ 4,000	$ 2,300

Supplemental Balance Sheet Information -Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 11,502	$ 7,361
Less: Accumulated depreciation	(3,143)	(2,529)
Property and equipment, net	8,359	4,832
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	5,860	5,587
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	198	198
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	125	125
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	467	467
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	246	246
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 4,606	$ 738

Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Payroll and employee-related costs	$ 2,926	$ 3,688
Research and development costs	10,318	5,533
Other current liabilities	917	666
Total accrued expenses and other current liabilities	$ 14,161	$ 9,887

Supplemental Balance Sheet Information - Schedule of Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Line Items]
Cash and cash equivalents	$ 104,582	$ 142,745
Construction in Progress [Member]
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Line Items]
Cash and cash equivalents	104,582		$ 50,902
Restricted cash	3,990		2,279
Cash, cash equivalents and restricted cash	$ 108,572		$ 53,181

Redeemable Convertible Preferred Stock - Additional Information (Details) $ / shares in Units, $ in Millions	1 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares	Jun. 30, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares
Class of Stock [Line Items]
Redeemable convertible preferred stock shares authorized \| shares		10,000,000	10,000,000
Preferred to Common exchange ratio		0.34
Redeemable convertible preferred stock Par or Stated Value Per Share \| $ / shares		$ 0.001	$ 0.001
Series B Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Redeemable convertible preferred stock issued during period shares new issues \| shares	22,686,025
Proceeds from Issuance of Redeemable Convertible Preferred Stock \| $	$ 30.0
Redeemable convertible preferred stock issue price per share \| $ / shares	$ 1.32
Redeemable convertible preferred stock Issuance Costs \| $	$ 0.1

Stock-Based Compensation - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($) shares	Aug. 10, 2021	Jun. 30, 2021
Merger Exchange Ratio	0.34	0.34	0.34
Stock Option Activity [Member]
Unrecognized compensation cost \| $	$ 42.5
Unrecognized compensation cost, weighted average period	2 years 10 months 24 days
Merger Exchange Ratio	0.34
2021 Plan [Member]
Share based payment arrangement, Shares reserved for future issuance	7,049,248
2021 Employee Stock Purchase Plan [Member]
Share based payment arrangement, Shares issued during period	42,553

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 3,425	$ 1,196	$ 6,630	$ 2,146
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	1,656	552	3,298	1,012
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 1,769	$ 644	$ 3,332	$ 1,134

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Beginning balance	9,372,993
Number of Shares Granted	4,132,175
Number of Shares Exercised	(357,212)
Number of Shares Cancelled	(713,745)
Number of Shares Ending balance	12,434,211	9,372,993
Number of Shares Options exercisable	3,096,025
Weighted Average Exercise Price Beginning balance	$ 5.59
Weighted Average Exercise Price Granted	8.88
Weighted Average Exercise Price Exercised	2.01
Weighted Average Exercise Price Cancelled	9.47
Weighted Average Exercise Price Ending balance	6.56	$ 5.59
Weighted Average Exercise Price Options exercisable	$ 3.16
Weighted Average Contractual Term	8 years 7 months 2 days	8 years 6 months 18 days
Weighted Average Contractual Term Options exercisable	7 years 3 days
Aggregate Intrinsic Value	$ 9,642,834	$ 51,415,394
Aggregate Intrinsic Value Options exercisable	$ 6,047,673

Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net loss	$ (24,858)	$ (25,208)	$ (4,493)	$ (12,106)	$ (50,066)	$ (16,599)
Denominator:
Weighted-average common stock outstanding - basic	87,839,804		48,524,511		87,775,440	45,088,434
Weighted-average common stock outstanding - diluted	87,839,804		48,524,511		87,775,440	45,088,434
Net loss per common share - basic	$ (0.28)		$ (0.09)		$ (0.57)	$ (0.37)
Net loss per common share - diluted	$ (0.28)		$ (0.09)		$ (0.57)	$ (0.37)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,434,211	6,500,261
Stock options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,434,211	6,494,737
Unvested restricted common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		5,524

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Tax provision or benefit	$ 3,000	$ (21,000)	$ 3,000	$ 53,000
Effective income tax rate	0.00%	(0.30%)	0.00%	(0.30%)
Forecasting Taxable Loss Position Deferred Tax Assets [Member]
Tax provision or benefit			$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details